trending Market Intelligence /marketintelligence/en/news-insights/trending/o1jcevc52u8jakpqjnzkaa2 content esgSubNav
In This List

Cardinal Health's stent-graft system gets US FDA panel backing for heart surgery

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Cardinal Health's stent-graft system gets US FDA panel backing for heart surgery

Cardinal Health Inc.'s stent-graft system was recommended by a U.S. Food and Drug Administration panel for use in heart surgery.

The stent system, called Incraft AAA Stent Graft System, is meant to treat infrarenal abdominal aortic aneurysms, or AAA — a weakened area in the aorta, the body's main artery, which can rupture and lead to a life-threatening hemorrhage if left untreated. AAA causes about 10,000 deaths in the U.S. every year.

Dublin, Ohio-based Cardinal Health said that while there are devices similar to Incraft already available, its ultra low-profile device is meant for AAA patients with small femoral or iliac arteries or with heavily calcified or tortuous vessels that could lead to complications during treatment.

The FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11-4 in favor of the Incraft system's approval. The device is commercially available in 39 countries, not including the U.S.

Cardinal Health's premarket approval application for Incraft is supported by data from a successful study, called Inspiration, where the survival rate after four years was nearly 80%.